InSysBio to launch its OpenSource HetaSimulator project

NEWS
Press-Release
August 11, 2021

August 11, 2021The new platform is a part of Heta-based QSP modeling infrastructure[Moscow – 11.08.2021] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, now presents HetaSimulator. It is a part of Heta project that embraces three components. HetaSimulator is an OpenSource simulation and parameters estimation platform for the Heta modeling language.

Heta language is a domain-specific modeling language (DSL) for dynamic quantitative models used in QSP and systems biology. Heta code and tabular formats can be translated into variety of formats like Simbiology, Matlab, DBSolve and many others.In general, the main purpose of the package is to establish the linkage between emerging QSP frameworks and fast computational methods. This package provides the simulation engines for the Heta-based models and modeling platforms to be run in Julia. A QSP model can be directly run using the HetaSimulator without additional tools. The ODE system in general form can also be run with HetaSimulator.The main features of the package are:- capabilities for finding parameters based on experimental datasets.- support for working with multiple models including simultaneous fitting.- parallel simulations facility including solution in clusters.- storage of components in unified format. - import of datasets and conditions from CSV/Excell tables.- full Heta standard support. Reading models from Heta-based platforms.- utilizing the facilities of OpenSource projects like Julia and SciML ecosystem.Evgeny Metelkin, PhD, Head of Development Department, comments on the project, “Heta infrastructure development is backed on years of our modeling experience and focus on the future that will turn computationally extensive tasks into routine modeling process. Initially, HetaSimulator was developed as a Julia language package. Our expectations have been met since Julia is one of the most rapidly evolving languages now. I believe that Heta project is the most functional and flexible environment to develop a modeling project or advisory applications”.The components of Heta infrastructure:- Heta standard: Series of specifications for QSP models and data.- Heta compiler: JavaScript library and console application for creating Heta-based platforms and transformation into popular formats.- Heta simulator: Julia based modeling engine for computationally extensive tasks.Oleg Demin, PhD, CEO of InSysBio, highlights the significance of the innovation, “The launch of HetaSimulator is a crucial step of a strategic goal to build full circle QSP modeling infrastructure. Today we are able both to efficiently develop large-scale QSP platforms based on Heta approach and have tremendous capability for conducting multiple simulations, parameters identification and identifiability analysis. We hope that our OpenSource project will contribute to advanced modeling techniques development and stimulate feedback from modeling community”.About InSysBioInSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 120 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.

July 2017
MoTuWeThFrSaSu
     
1
2
3
4
5
6
7
8
9
10
11
12
13
14
1. 14 Jul 2017 18:49 To predict unpredictable: a platform for modeling of the high-selective oncology drugs was created Moscow, Russia, July 14, 2017. The scientists from BIND RUS and InSysBio (www.insysbio.ru) published a joint research of the new class of anti-oncology treatment in the Journal of Controlled Release. Unique nanoparticles enriched with medications can deliver its content targeted to the tumor site, and the parameters of their effectiveness are programmed during the forming phase.
15
16
17
18
19
20
21
22
23
24
25
1. 25 Jul 2017 13:50 InSysBio LLC Announce Renewal of Agreement with ASTEX Pharmaceuticals Inc. Moscow, Russia, July 25, 2017 – InSysBio LLC (www.insysbio.ru), one of the pioneers in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, announced today a renewal of multi-year Master Service Agreement with ASTEX Pharmaceuticals, Inc.
2. 25 Jul 2017 17:37 InSysBio will present at the American Conference on Pharmacometrics (ACoP8)! Moscow, Russia, July 26, 2017. - Event announcement. This year the scientific team of InSysBio will make 9 poster presentations in conjunction with leading pharmaceutical companies at ACoP8. Also at the special session "QSP Modular design - Approaches to speed up the QSP model development" Oleg Demin Jr will hold a workshop on modeling with the Immune Response Template (IRT) platform.
26
27
28
29
30
31
      
Upcoming Events
Tags
Latest News
28.01
InSysBio to announce a new collaborative project with BeOne Medicines
29.10
InSysBio to announce its collaboration with BeOne Medicines
16.10
InSysBio to introduce a new data annotation service available in CYTOCON DB and fIVE DB
19.08
InSysBio to publish the new article "Revolutionizing drug discovery: Integrating artificial intelligence with quantitative systems pharmacology"
05.08
InSysBio to launch Immune Response Template Open for QSP modeling